Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | CTSV | O60911 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486492 | 0.86 | MAPT (0.48) | TDO2ARMEN1NPC1RAB9A | |
| SCHEMBL311078 | 0.84 | MAPT (0.37) | MEN1NPC1RAB9AKMT2AMAPT | |
| SCHEMBL1486746 | 0.84 | NPC1 (0.46) | TDO2ARMEN1NPC1RAB9A | |
| SCHEMBL311966 | 0.83 | MEN1 (0.43) | TDO2ARMEN1NPC1RAB9A | |
| SCHEMBL1486472 | 0.83 | TDO2 (0.42) | TDO2ARMEN1NPC1RAB9A | |
| SCHEMBL1486584 | 0.83 | MEN1 (0.42) | TDO2ARMEN1NPC1RAB9A | |
| SCHEMBL3875765 | 0.81 | MAPT (0.44) | TDO2ARMEN1NPC1RAB9A | |
| SCHEMBL3875764 | 0.81 | MAPT (0.44) | TDO2ARMEN1NPC1RAB9A | |
| SCHEMBL1962206 | 0.81 | MAPT (0.40) | TDO2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1233933 | 0.81 | BCL2 (0.44) | TDO2MEN1KMT2AMAPTBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093390-B2 | Substituted fused [1,2]imidazo[4,5-C] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090005371-A1 | Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-01 | — | — | US | disclosed |
| EP-1845986-A2 | SUBSTITUTED FUSED [1,2]IMIDAZO[4,5-C]RING COMPOUNDS AND METHODS | Coley Pharmaceutical Group, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006086633-A2 | SUBSTITUTED FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005371-A1 | Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods | IL2, IFNG, IL4 | TDO2 3056/4885AR 2858/4885MEN1 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.